|
|
Blood, 1 May 2008, Vol. 111, No. 9, pp. 4797-4808.
Prepublished online as a Blood First Edition Paper on February 12, 2008; DOI 10.1182/blood-2007-09-113027.
Previous Article | Next Article 
Submitted September 17, 2007
Accepted December 19, 2007
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia
Michael H Tomasson*, Zhifu Xiang, Richard Walgren, Yu Zhao, Yumi Kasai, Tracie Miner, Rhonda E Ries, Olga Lubman, Daved Fremont, Michael D McLellan, Jacqueline E Payton, Peter Westervelt, John F DiPersio, Daniel C Link, Matthew J Walter, Timothy A Graubert, Mark Watson, Jack Baty, Sharon Heath, William D Shannon, Rakesh Nagarajan, Clara D. Bloomfield, Elaine R. Mardis, Richard K Wilson, and Timothy J Ley
Division of Oncology, Department of Medicine, Washington University, St. Louis, MO, United States
Genome Sequencing Center, Washington University, St. Louis, MO, United States
Department of Pathology and Immunology, Washington University, St. Louis, MO, United States
Division of Biostatistics, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, United States
Cancer and Leukemia Group B, Ohio State University Comprehensive Cancer Center, Ohio State University, Columbus, OH, United States
* Corresponding author; email: tomasson{at}wustl.edu.
Activating mutations in tyrosine kinase (TK) genes (e.g. FLT3 and KIT) are found in more than 30% of patients with de novo acute myeloid leukemia (AML); many groups have speculated that mutations in other TK genes may be present in the remaining 70%. We performed high-throughput re-sequencing of the kinase domains of 26 TK genes (11 receptor TK and 15 cytoplasmic TK) that are expressed in most AML patients, using genomic DNA from the bone marrow (tumor) and matched skin biopsy samples ("germline") from 94 patients with de novo AML; sequence variants were validated in an additional 94 AML tumor samples (14.3 million base pairs of sequence were obtained and analyzed). We identified known somatic mutations in FLT3, KIT, and JAK2 TK genes at the expected frequencies, and found four novel somatic mutations, JAK1V623A, JAK1T478S, DDR1A803V and NTRK1S677N, once each in four respective patients out of 188 tested. We also identified novel germline sequence changes encoding amino acid substitutions (i.e. non-synonymous changes) in 14 TK genes, including TYK2, which had the largest number of non-synonymous sequence variants (11 total detected). Additional studies will be required to define the roles that these somatic and germline TK gene variants play in AML pathogenesis.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
Hitchhikers' guide to the leukemia genome
- Nicholas C. P. Cross
Blood 2008 111: 4428-4429.
[Full Text]
[PDF]
| |